

Dr. Sandeep Gupta

**SVP – Drug Discovery & Early Development,
Endo Pharmaceuticals**

Dr. Sandeep Gupta is the Senior Vice President of Drug Discovery and Early Development at Endo Pharmaceuticals Inc. based in Chadds Ford, PA. At Endo, Dr. Gupta oversees all aspects of research and development activities in oncology, pain, urology and endocrinology therapeutic areas from discovery stage to Phase 1. He has devised and implemented a semi-virtual drug discovery model and established a number of successful collaborations in India and Europe. Dr. Gupta has established a robust discovery and early development pipeline at Endo which includes small molecules as well as biologics. He also played a key role in the development of crush resistant formulation of Oxymorphone, which was recently approved by the FDA.

Prior to joining Endo, Dr. Gupta served as Head of Drug Discovery and Pharmacology at Forest Laboratories. He made key contributions to 4 NDAs (including Lexapro and Namenda) and several INDs during his tenure at Forest. Dr. Gupta joined Forest in 1998 after nearly a decade in academia, including faculty positions at the University of Pennsylvania's Department of Surgery/Urology and Boston University School of Medicine (Diabetes/ Metabolism and Urology). He graduated with a BS in Pharmacy from Banaras Hindu University in India in 1982 and earned his Doctorate in Pharmacology from the Northeastern University, Boston in 1989.

Some of the key drug discovery and development areas in which Dr. Gupta has been involved and has extensive experience include depression, schizophrenia, Alzheimer's disease, neuropathic pain, arthritis, asthma, chronic obstructive pulmonary disease, hypertension, type II diabetes, overactive bladder, erectile dysfunction and oncology.

Dr. Gupta is a member of the American Diabetes Association, the European Association for the Study of Diabetes, the American Urological Association, the American Association for Cancer Research and the American Society of Clinical Oncology.
